News

Altan Pharma Submits New Drug Application for Acetaminophen Solution for Infusion for Treatment of Pain and Reduction of Fever

February 7, 2019

NDA filed and Accepted for Review by US FDA Opportunity to enter $300m+ US market for intravenous formulations of paracetamol Dublin, February 7, 2019, Altan Pharma Limited (“Altan”), an Irish specialty pharmaceutical company, today announces that it has submitted a New Drug Application (NDA) for its formulation of acetaminophen solution for infusion to the United… View Article

Altan Pharma Announces the Grant of Two Patents by the USPTO Covering its Unique, Intravenous Formulation of Acetaminophen

April 17, 2018

Dublin, April 17, 2018, Altan Pharma Limited (“Altan”), an Irish specialty pharmaceutical company, today announced that the United States Patent and Trademark Office (“USPTO”) has granted two patents to Altan covering its intravenous formulation of acetaminophen (paracetamol). U.S. Patent No. 9,943,479 covers Altan’s unique formulation, which allows the product to be packaged in a flexible plastic… View Article

Altan Pharma Announces Licensing Agreement for Generic of Antifungal Agent Caspofungin

March 4, 2016

Altan Pharma Limited (“Altan”), an Irish specialty pharmaceutical company, today announced that it has signed a licensing agreement to commercialise a generic version of caspofungin. The agreement covers the territories of Germany, France, Italy, Spain, the United Kingdom, Belgium, Portugal, Poland and Latin America. Chairman and Chief Executive Officer of Altan Pharma, Guillermo Herrera stated:… View Article

Altan Pharma Announces the Launch of Linezolid 2mg/ml Solution for Infusion in Spain

March 3, 2016

Altan Pharma Limited (“Altan”), an Irish specialty pharmaceutical company today announced that it has launched linezolid 2mg/ml solution for infusion for the treatment of community acquired pneumonia and nosocomial pneumonia in Spain through its Spanish subsidiary Genéricos Españoles Laboratorio, S.A.U. According to IMS, the market for Linezolid solution for infusion in Spain was roughly €23… View Article

Altan Announces Acquisition of the GES Group

June 10, 2015

Altan Pharma Limited (“Altan”), an Irish specialty pharmaceutical company today announced that it has acquired a privately held group of Spanish companies, The GES Group (“GES”). The GES Group develops, manufactures and markets specialty injectable drugs. GES, headquartered in Spain, is comprised of three operating companies: GES Genéricos Españoles Laboratorio, S.A.U.; Genfarma Laboratorio, S.L. and… View Article